Human Genome Sciences, Inc (HGSI)

[chmcnfunds]

Human Genome (HGSI) Affirms New Albiglutide from Glaxo (GSK)

April 3, 2012 7:46 AM EDT

HGSI Hot Sheet
Overall Analyst Rating:
NEUTRAL (= Flat)

Revenue Growth %: +113.6%

Human Genome (Nasdaq: HGSI) reports that GlaxoSmithKline (NYSE: GSK) issued an update on its Phase III of Albiglutide. For more color, click here.

Albiglutide was created by HGS using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million – including $33.0 million received to date – in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized.

All inquiries regarding the albiglutide Phase 3 data announced today should be directed to the contacts provided by GSK.
__________________________________________________________
http://www.streetinsider.com/Corporate+News/Human+Genome+(HGSI)+Affirms+New+Albiglutide+from+Glaxo+(GSK)/7317043.html

HGSI